CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Par Pharmaceutical Companies, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Par Pharmaceutical Companies, Inc.
1 Ram Ridge Rd
Phone: (845) 573-5500p:845 573-5500 Chestnut Ridge, NY  10977  United States
Filed for Bankruptcy on 8/16/2022
This company was Merged or Acquired on 9/28/2015.
Case #22-22576, filed in the U.S. Bankruptcy Court for the Southern District of New York (White Plains)
This case is being Jointly Administered under the lead case filed for Endo International plc Case #22-22549.
This is a Subsidiary, click here for the Parent Company
Business Summary
Par Pharmaceutical Companies, Inc. is a holding company. The Company, through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., specializes in developing, licensing, manufacturing, marketing and distributing generic drugs in the United States. It has a generics portfolio of around 95 products across a of dosage forms and delivery systems, including immediate and extended release oral solids (tablets, orally disintegrating tablets, capsules and powders), injectables, nasal sprays, ophthalmics and transdermal patches. The Company operates in two business segments: Par Pharmaceutical (Par) segment, which includes both generic products marketed under Par Pharmaceutical and sterile products marketed under Par Sterile Products, LLC (Par Sterile Products or Par Sterile) and Par Specialty Pharmaceuticals (Par Specialty) segment, which markets two branded products. The Company has around 200 products in its pipeline.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201512/31/2014YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer Paul V.Campanelli 58 1/1/2015 2/1/2007
Chief Financial Officer, Executive Vice President Michael A.Tropiano 57 1/1/2015 7/1/2010
Chief Operating Officer Terrance J.Coughlin 55 4/1/2014 4/1/2014
Chief Administrative Officer, General Counsel Thomas J.Haughey 56 1/1/2015 9/1/2012

Business Names
Business Name
Anchen Incorporated
Anchen Pharmaceuticals, Inc.
JHP Acquisition, LLC
8 additional Business Names available in full report.

General Information
Shareholders: 1,422
Stock Exchange: NYSE
Federal Tax Id: 813078301


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023